|Dr. Kevin C. Gorman||CEO & Director||1.15M||22.04M||1958|
|Mr. Matthew C. Abernethy||Chief Financial Officer||689.24k||N/A||1980|
|Mr. Kyle W. Gano||Chief Bus. Devel. and Strategy Officer||602.64k||4.93M||1973|
|Mr. Eric S. Benevich||Chief Commercial Officer||676.85k||N/A||1965|
|Ms. Eiry Wyn Roberts||Chief Medical Officer||1.39M||N/A||1964|
Neurocrine Biosciences, Inc. discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company offers INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for use in women's health. Its product candidates in clinical development include elagolix that is in Phase III clinical trial for Uterine Fibroids; opicapone, a catechol-O-methyltransferase inhibitor, which is in Phase III clinical trial that is used for in adjunct therapy and preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease; and NBI-74788, which is in Phase II clinical trial for the treatment of congenital adrenal hyperplasia. The company's product candidates also comprise VMAT2 Inhibitors and which are in Phase I clinical trial for neurology/psychiatry disorders. It has collaborations and agreements with AbbVie Inc. to develop and commercialize elagolix and GnRH antagonists for women's and men's health; Mitsubishi Tanabe Pharma Corporation to develop and commercialize INGREZZA for movement disorders; and BIAL Portela & Ca, S.A. to develop and commercialize opicapone for the treatment of human diseases and conditions, including Parkinson's disease. Neurocrine Biosciences, Inc. also has a research collaboration agreement with Jnana Therapeutics Inc. to discover small molecule therapeutics for central nervous system disorders; a collaboration and license agreement with Voyager Therapeutics, Inc. for the research, development, and commercialization of VY-AADC program for Parkinson's disease and VY-FXN01 program for Friedreich's ataxia; and license and collaboration agreement with Xenon Pharmaceuticals Inc. for developing treatments for epilepsy. Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California.
Neurocrine Biosciences, Inc.’s ISS Governance QualityScore as of October 4, 2019 is 6. The pillar scores are Audit: 1; Board: 8; Shareholder Rights: 5; Compensation: 4.